209 related articles for article (PubMed ID: 37324940)
21. LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway.
Xu F; Huang M; Chen Q; Niu Y; Hu Y; Hu P; Chen D; He C; Huang K; Zeng Z; Tang J; Wang F; Zhao Y; Wang C; Zhao G
Cancer Res; 2021 Nov; 81(22):5678-5691. PubMed ID: 34593522
[TBL] [Abstract][Full Text] [Related]
22. Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells.
Kitagawa K; Moriya K; Kaji K; Saikawa S; Sato S; Nishimura N; Namisaki T; Akahane T; Mitoro A; Yoshiji H
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066548
[TBL] [Abstract][Full Text] [Related]
23. MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type.
Shibahara H; Tamada S; Higashi M; Goto M; Batra SK; Hollingsworth MA; Imai K; Yonezawa S
Hepatology; 2004 Jan; 39(1):220-9. PubMed ID: 14752841
[TBL] [Abstract][Full Text] [Related]
24. Apicidin sensitizes pancreatic cancer cells to gemcitabine by epigenetically regulating MUC4 expression.
Ansari D; Urey C; Hilmersson KS; Bauden MP; Ek F; Olsson R; Andersson R
Anticancer Res; 2014 Oct; 34(10):5269-76. PubMed ID: 25275019
[TBL] [Abstract][Full Text] [Related]
25. Arsenic trioxide sensitizes pancreatic cancer cells to gemcitabine through downregulation of the TIMP1/PI3K/AKT/mTOR axis.
Tian Z; Tan Y; Lin X; Su M; Pan L; Lin L; Ou G; Chen Y
Transl Res; 2023 May; 255():66-76. PubMed ID: 36400307
[TBL] [Abstract][Full Text] [Related]
26. Terminal fucose mediates progression of human cholangiocarcinoma through EGF/EGFR activation and the Akt/Erk signaling pathway.
Indramanee S; Sawanyawisuth K; Silsirivanit A; Dana P; Phoomak C; Kariya R; Klinhom-On N; Sorin S; Wongkham C; Okada S; Wongkham S
Sci Rep; 2019 Nov; 9(1):17266. PubMed ID: 31754244
[TBL] [Abstract][Full Text] [Related]
27. Combined Gemcitabine and Metronidazole Is a Promising Therapeutic Strategy for Cancer Stem-like Cholangiocarcinoma.
Kawamoto M; Umebayashi M; Tanaka H; Koya N; Nakagawa S; Kawabe K; Onishi H; Nakamura M; Morisaki T
Anticancer Res; 2018 May; 38(5):2739-2748. PubMed ID: 29715094
[TBL] [Abstract][Full Text] [Related]
28. Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression.
Guo Z; Wang F; Di Y; Yao L; Yu X; Fu D; Li J; Jin C
Int J Nanomedicine; 2018; 13():4869-4880. PubMed ID: 30214194
[TBL] [Abstract][Full Text] [Related]
29. High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy.
Quintavalle C; Burmeister K; Piscuoglio S; Quagliata L; Karamitopoulou E; Sepe R; Fusco A; Terracciano LM; Andersen JB; Pallante P; Matter MS
Mol Carcinog; 2017 Sep; 56(9):2146-2157. PubMed ID: 28467612
[TBL] [Abstract][Full Text] [Related]
30. GDC-0980 (apitolisib) treatment with gemcitabine and/or cisplatin synergistically reduces cholangiocarcinoma cell growth by suppressing the PI3K/Akt/mTOR pathway.
Jang DK; Lee YG; Chan Chae Y; Lee JK; Paik WH; Lee SH; Kim YT; Ryu JK
Biochem Biophys Res Commun; 2020 Sep; 529(4):1242-1248. PubMed ID: 32819590
[TBL] [Abstract][Full Text] [Related]
31. Human equilibrative nucleoside transporter 1 expression predicts survival of advanced cholangiocarcinoma patients treated with gemcitabine-based adjuvant chemotherapy after surgical resection.
Kobayashi H; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
Ann Surg; 2012 Aug; 256(2):288-96. PubMed ID: 22580938
[TBL] [Abstract][Full Text] [Related]
32. Low‑intensity low‑frequency ultrasound enhances the chemosensitivity of gemcitabine‑resistant ASPC‑1 cells via PI3K/AKT/NF‑κB pathway‑mediated ABC transporters.
Qiu F; Chen J; Cao J; Diao F; Huang P
Oncol Rep; 2020 Sep; 44(3):1158-1168. PubMed ID: 32705228
[TBL] [Abstract][Full Text] [Related]
33. Identification of chemoresistance-related mRNAs based on gemcitabine-resistant pancreatic cancer cell lines.
Zhou J; Zhang L; Zheng H; Ge W; Huang Y; Yan Y; Zhou X; Zhu W; Kong Y; Ding Y; Wang W
Cancer Med; 2020 Feb; 9(3):1115-1130. PubMed ID: 31823522
[TBL] [Abstract][Full Text] [Related]
34. Hypoxia-induced SKA3 promoted cholangiocarcinoma progression and chemoresistance by enhancing fatty acid synthesis via the regulation of PAR-dependent HIF-1a deubiquitylation.
Chen Y; Xu X; Wang Y; Zhang Y; Zhou T; Jiang W; Wang Z; Chang J; Liu S; Chen R; Shan J; Wang J; Wang Y; Li C; Li X
J Exp Clin Cancer Res; 2023 Oct; 42(1):265. PubMed ID: 37821935
[TBL] [Abstract][Full Text] [Related]
35. Amplified in breast cancer 1 enhances human cholangiocarcinoma growth and chemoresistance by simultaneous activation of Akt and Nrf2 pathways.
Chen Q; Li W; Wan Y; Xia X; Wu Q; Chen Y; Lai Z; Yu C; Li W
Hepatology; 2012 Jun; 55(6):1820-9. PubMed ID: 22213475
[TBL] [Abstract][Full Text] [Related]
36. MiR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs.
Yang R; Wang D; Han S; Gu Y; Li Z; Deng L; Yin A; Gao Y; Li X; Yu Y; Wang X
Int J Biol Sci; 2022; 18(1):43-64. PubMed ID: 34975317
[No Abstract] [Full Text] [Related]
37. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
38. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
[TBL] [Abstract][Full Text] [Related]
39. Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells.
Nakajima Y; Takagi H; Kakizaki S; Horiguchi N; Sato K; Sunaga N; Mori M
Anticancer Res; 2012 Dec; 32(12):5251-62. PubMed ID: 23225424
[TBL] [Abstract][Full Text] [Related]
40. ARID1A Mutation from Targeted Next-Generation Sequencing Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer.
Lee SH; Cheon J; Lee S; Kang B; Kim C; Shim HS; Park YN; Jung S; Choi SH; Choi HJ; Lee CK; Chon HJ
Cancer Res Treat; 2023 Oct; 55(4):1291-1302. PubMed ID: 37139666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
